2C-H

2C-H, or 2,5-dimethoxyphenethylamine, is a lesser-known substituted phenethylamine of the 2C family. 2C-H, or 2,5-dimethoxyphenethylamine, is a lesser-known substituted phenethylamine of the 2C family. 2C-H was first synthesized in 1932 by Johannes S. Buck. 2C-H is used as a precursor in the synthesis of other substituted phenethylamines such as 2C-B, 2C-I, and 2C-N. 2C-H has been found in trace amounts by the DEA's south central laboratory in tablets that were suspected of containing MDMA. There is no record of 2C-H trials in humans, as it would likely be destroyed by monoamine oxidase enzymes before causing any significant psychoactive effects. In the book PiHKAL (Phenethylamines i Have Known And Loved), Alexander Shulgin lists both the dosage and duration of 2C-H effects as unknown. Very little data exists about the pharmacological properties, metabolism, and toxicity of 2C-H. It exhibits agonist activity at human trace amine associated receptor 1 expressed in RD-HGA16 CHO-K1 cells coexpressed with Galpha16 protein assessed as internal calcium mobilization. 2C-H was found to be inactive in NCI In Vivo Anticancer Drug Screens for tumor model L1210 Leukemia. It was found to be an active Alpha-1 adrenergic receptor agonist in rabbit ear arteries. It has binding affinity towards 5-HT2C and 5-HT2A receptors in rats. It features competitive antagonist activity at 5-HT serotonin receptor in Sprague-Dawley rat stomachs. It exhibits binding affinity against rat 5-hydroxytryptamine 2C receptors using mesulergine as a radioligand. As of October 31, 2016; 2C-H is a controlled substance (Schedule III) in Canada. http://gazette.gc.ca/rp-pr/p2/2016/2016-05-04/html/sor-dors72-eng.php As of July 9, 2012, 2C-H is a Schedule I controlled substance in the United States, under the Synthetic Drug Abuse Prevention Act of 2012. 2C-H's DEA Drug Code is 7517.